Immunoprecise Antibodies Ltd Share Price Other OTC
Equities
CA87588T1030
Pharmaceuticals
Sales 2024 * | 24.59M 18.03M 1.42B | Sales 2025 * | 29.82M 21.87M 1.72B | Capitalization | 39.83M 29.21M 2.29B |
---|---|---|---|---|---|
Net income 2024 * | -12M -8.8M -691M | Net income 2025 * | -9M -6.6M -518M | EV / Sales 2024 * | 1.62 x |
Net cash position 2024 * | - 0 0 | Net cash position 2025 * | - 0 0 | EV / Sales 2025 * | 1.34 x |
P/E ratio 2024 * |
-3.16
x | P/E ratio 2025 * |
-4.28
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 86.41% |
Latest transcript on Immunoprecise Antibodies Ltd
Managers | Title | Age | Since |
---|---|---|---|
Jennifer Bath
CEO | Chief Executive Officer | - | 20/02/18 |
Kristin Taylor
DFI | Director of Finance/CFO | - | 28/09/23 |
Ilse Roodink
CTO | Chief Tech/Sci/R&D Officer | - | 30/06/21 |
Members of the board | Title | Age | Since |
---|---|---|---|
Mitchell Levine
CHM | Chairman | - | - |
Chris Buyse
BRD | Director/Board Member | 59 | 04/09/23 |
Jennifer Bath
CEO | Chief Executive Officer | - | 20/02/18 |
1st Jan change | Capi. | |
---|---|---|
-2.29% | 89.87B | |
-3.95% | 37.57B | |
-13.07% | 32.75B | |
+63.05% | 26.47B | |
-22.14% | 14.25B | |
-7.96% | 12.99B | |
-9.33% | 11.93B | |
-46.33% | 10.84B | |
+5.77% | 9.11B |